Spero Therapeutics Inc.

NASDAQ: SPRO · Real-Time Price · USD
1.93
-0.05 (-2.53%)
At close: Aug 15, 2025, 3:59 PM
2.00
3.88%
After-hours: Aug 15, 2025, 07:31 PM EDT

Spero Therapeutics Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-68.57M 22.81M -46.41M -89.76M
Depreciation & Amortization
2K 367K 869K 646K
Stock-Based Compensation
7.79M 7.93M 9.12M 9.43M
Other Working Capital
31.9M -70.67M 21.02M 9.08M
Other Non-Cash Items
1.04M 6.28M 6.61M 2.37M
Deferred Income Tax
n/a n/a n/a 60K
Change in Working Capital
36.28M -70.38M 22.09M 12.9M
Operating Cash Flow
-23.44M -32.99M -7.73M -64.35M
Capital Expenditures
n/a n/a n/a 39K
Cash Acquisitions
n/a n/a n/a -39K
Purchase of Investments
n/a n/a -26.97M -43.91M
Sales Maturities Of Investments
n/a n/a 60.78M 51.55M
Other Investing Acitivies
n/a n/a n/a 39K
Investing Cash Flow
n/a n/a 33.81M 7.67M
Debt Repayment
n/a n/a -54.48M 47.48M
Common Stock Repurchased
n/a n/a n/a n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
n/a n/a 420K 1.2M
Financial Cash Flow
n/a 221K -29.55M 84.05M
Net Cash Flow
-23.44M -32.77M -3.48M 27.38M
Free Cash Flow
-23.44M -32.99M -7.73M -64.31M